share_log

DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis

DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis

DURECT公司获得美国食品药品管理局对Larsucosterol治疗酒精相关性肝炎的突破性疗法认定
Benzinga ·  05/21 20:03

DURECT Corporation Receives FDA Breakthrough Therapy Designation For Larsucosterol In Alcohol-Associated Hepatitis

DURECT公司获得美国食品药品管理局对Larsucosterol治疗酒精相关性肝炎的突破性疗法认定

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发